Cure8 research brief
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new treatments or adjunct therapies for IBD.
Researchers studying IBD therapeutics, microbiome-focused investigators, clinicians interested in translational IBD research, and patients curious about preclinical research on complementary therapies.
This study reports that Qijiao Shengbai capsule (QJSB), a traditional Chinese herbal formulation, improved disease measures in a mouse model of DSS-induced ulcerative colitis. Treated mice showed less weight loss, lower disease activity scores, reduced colon damage, and decreases in pro-inflammatory markers (TNF-α, IL-6, IL-1β), LPS, and MPO.
The authors combined metabolomics, 16S rRNA sequencing, and network pharmacology to explore mechanisms.
They report that QJSB altered gut microbial composition (higher Akkermansia and Lactobacillus; lower Bacteroides), shifted metabolic pathways involving amino acids and polyunsaturated fatty acids, improved intestinal barrier markers, and that Western blots were consistent with suppression of the TLR4/MyD88/NF-κB pathway.
These results are from an animal (mouse) model and laboratory assays rather than human clinical trials. The paper suggests QJSB as a potential candidate for UC therapy and provides mechanistic data, but it does not provide evidence of safety or efficacy in people.
These findings are from mice and laboratory analyses (structured content depth: abstract). Animal-model effects do not predict human benefit or safety. The study uses multi-omics and pathway analysis to generate hypotheses that would require clinical testing before any recommendation for patients.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This preclinical study links cod skin–derived collagen peptides to reduced colitis severity in mice through changes in the gut microbiota and suppression of the NLRP3 inflammasome — pathways that could be relevant to...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
